New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
10:01 EDTAEGN, RUSHA, RXN, QSII, PHG, PNR, TV, LLY, CTCM, BRO, TTMOn The Fly: Analyst Downgrade Summary
Aegion (AEGN) downgraded to Neutral from Buy at Sidoti... Brown & Brown (BRO) downgraded to Neutral from Buy at Compass Point... CTC Media (CTCM) downgraded to Underperform from Neutral at Credit Suisse... Eli Lilly (LLY) downgraded to Neutral from Buy at MKM Partners... Grupo Televisa (TV) downgraded to Underperform from Neutral at BofA/Merrill... Pentair (PNR) downgraded to Neutral from Outperform at Wedbush... Philips (PHG) downgraded to Sector Perform from Outperform at RBC Capital... Quality Systems (QSII) downgraded to Underweight from Equal Weight at Morgan Stanley... Rexnord (RXN) downgraded at BofA/Merrill... Rush Enterprises (RUSHA) downgraded to Equal Weight from Overweight at Stephens... Tata Motors (TTM) downgraded to Neutral from Outperform at Credit Suisse.
News For AEGN;BRO;CTCM;LLY;TV;PNR;PHG;QSII;RXN;RUSHA;TTM From The Last 14 Days
Check below for free stories on AEGN;BRO;CTCM;LLY;TV;PNR;PHG;QSII;RXN;RUSHA;TTM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
11:20 EDTPHGPhilips selects Morgan Stanley for lighting unit stake sale, Reuters says
Subscribe for More Information
July 24, 2014
09:26 EDTLLYEli Lilly CEO says company on track to meet FY goals
Subscribe for More Information
08:03 EDTPHGPhilips receives FDA 510(k) clearance for mobile ultrasound system
Subscribe for More Information
06:38 EDTLLYEli Lilly says Q2 revenue declined 17% due to patent expirations
Subscribe for More Information
06:37 EDTLLYEli Lilly sees research, development charge of $45M in Q3
In July, Eli Lilly announced a co-discovery and co-development collaboration with Immunocore to research and potentially develop novel T cell-based cancer therapies. As a result of the transaction, the company expects to incur an in-process research and development charge of $45M, or approximately 3c per share Q3. In Q2, the company recognized asset impairment, restructuring and other special charges of $63.5M, primarily related to costs associated with the decision to close a packaging and distribution facility in Germany.
06:35 EDTLLYEli Lilly reaffirms 2014 EPS outlook $2.72-$2.80, consensus $2.78
Subscribe for More Information
06:33 EDTLLYEli Lilly reports Q2 EPS 68c, consensus 65c
Reports Q2 revenue $4.94B, consensus $4.9B.
05:52 EDTQSIIQuality Systems reports Q1 EPS 13c, consensus 14c
Subscribe for More Information
July 23, 2014
15:30 EDTLLYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
14:06 EDTLLYEarnings Preview: Lilly counts on newer drugs to drive revenue
Subscribe for More Information
13:33 EDTPHGWi-LAN enters into license agreement with Philips
Wi-LAN (WILN) announced that the company's subsidiary, Open Network Solutions, has entered into a license agreement with Philips (PHG) and Philips Electronics North America Corporation. The licensed patents relate to networking capabilities of non-standard devices. The remaining terms of the license agreement are confidential.
July 22, 2014
16:24 EDTRUSHARush Enterprises reports Q2 EPS 49c, consensus 42c
Reports Q2 revenue $1.2B, consensus $1.02B.
10:00 EDTQSIIOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Abengoa Yield (ABY) initiated with an Equal Weight at Morgan Stanley... Actinium Pharmaceuticals (ATNM) initiated with a Buy at Canaccord... Axys Technologies (AXYS) initiated with a Buy at Dougherty... Chambers Street Properties (CSG) initiated with a Neutral at SunTrust... Enphase Energy (ENPH) initiated with a Buy at Dougherty... Minerals Technologies (MTX) initiated with an Outperform at Wedbush... NextEra Energy Partners (NEP) initiated with a Buy at BofA/Merrill... PTC Therapeutics (PTCT) initiated with a Buy at BofA/Merrill... QIWI (QIWI) initiated with a Positive at Susquehanna... Quality Systems (QSII) initiated with a Buy at Topeka... Sarepta (SRPT) initiated with a Neutral at BofA/Merrill... Trinseo S.A. (TSE) initiated with a Buy at BofA/Merrill... Washington Prime Group (WPG) initiated with a Neutral at SunTrust... Zhaopin (ZPIN) initiated with a Buy at UBS.
July 21, 2014
19:45 EDTBROBrown & Brown board approves $200M stock buyback
Subscribe for More Information
19:37 EDTBROBrown & Brown reports Q2 pro forma EPS 38c, consensus 42c
Subscribe for More Information
19:21 EDTQSIIQuality Systems initiated with a Buy at Topeka
Subscribe for More Information
06:11 EDTPHGPhilips sees second half EBITA above last year
Subscribe for More Information
06:10 EDTPHGPhilips reports Q2 net income EUR 0.26 vs. EUR 0.35 last year
Reports Q2 revenue EUR 5.29B vs. EUR 5.63B last year. Healthcare comparable sales decreased 4%. Consumer Lifestyle comparable sales increased by 7%. Lighting comparable sales increased 1% year-on-year.
July 16, 2014
08:21 EDTLLYEli Lilly reports beta-amyloid imaging results in Alzheimer's Disease
Subscribe for More Information
07:05 EDTLLYEli Lilly and Immunocore partner to develop cancel therapies
Eli Lilly and Immunocore today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies. Immunocore will receive an upfront fee of $15M per program for the discovery of novel ImmTACs against jointly-selected cancer targets in order to generate preclinical candidate packages. If Lilly accepts a preclinical candidate package to develop and potentially commercialize, Immunocore will receive an opt-in fee of $10M and will have an option to continue co-development with Lilly on a cost-sharing and profit-sharing basis. If Immunocore does not exercise its option, it will be entitled to potential future significant milestone and royalty payments.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use